NEUPOGEN STUDY RESULTS REPORTED

Researchers affiliated with The International Acute Myeloid Leukemia Study have reported that the use of Neupogen (filgrastim) to support intensive induction and consolidation chemotherapy does not affect long-term survival of patients with acute myeloid leukemia (AML). The details of this randomized Phase III study appeared in the journal Leukemia .

The study included a total of 521 adult patients with AML who were randomly allocated to receive Neupogen or placebo following induction and consolidation chemotherapy. Neupogen hastened neutrophil recovery by 5 days compared to placebo. This was accompanied by less fever, fewer parenteral antibiotics, including amphotericin B, and shorter hospitalization times with no apparent impact on survival or relapses.